{"id":"W2494947788","doi":"10.1200/jco.2016.34.15_suppl.9007","title":"Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; ALK inhibitor; Internal medicine; Refractory (planetary science); Lung cancer; non-small cell lung cancer (NSCLC); Response Evaluation Criteria in Solid Tumors; Ceritinib; Gastroenterology; Randomized controlled trial; Phases of clinical research; Clinical trial; Surgery; Oncology; Malignant pleural effusion","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001943235,0.0002332318,0.002720327,0.000139042,0.00004747001,0.000007493285,0.0001176309,0.0003132405,0.0002659579],"category_scores_gemma":[0.003200324,0.0001229792,0.0004214858,0.0001169753,0.0003775611,0.0001444105,0.00004174854,0.0005257368,0.00000216122],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003012441,"about_ca_system_score_gemma":0.00294774,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00051355,"about_ca_topic_score_gemma":0.0003143655,"domain_scores_codex":[0.9948474,0.0004457314,0.003684429,0.0003450892,0.0004164281,0.0002609909],"domain_scores_gemma":[0.9892729,0.005711427,0.003796658,0.0002557476,0.0005450705,0.0004182086],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8363082,0.009817798,0.1042099,0.00004650271,0.001262229,0.0007389787,0.0004685833,0.000005145109,0.00008740229,0.000004022166,0.0007545349,0.04629673],"study_design_scores_gemma":[0.8462183,0.01629609,0.128023,0.0008591945,0.002264451,0.00004066063,0.00003708186,0.00002397088,0.00006850748,0.00001966981,0.006020923,0.0001281998],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921563,0.0004934004,0.0002898498,0.002123949,0.001284532,0.001689606,0.00007185891,0.000006945239,0.001883605],"genre_scores_gemma":[0.9957739,0.001025584,0.001599973,0.0003256923,0.0008807097,0.0000414183,0.00002049846,0.00002940658,0.0003027763],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04616853,"threshold_uncertainty_score":0.5229164,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03449083937050493,"score_gpt":0.4326835096161204,"score_spread":0.3981926702456154,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}